{"id":1059,"date":"2019-03-19T14:43:39","date_gmt":"2019-03-19T13:43:39","guid":{"rendered":"https:\/\/www.francecoag.org\/?post_type=publications_science&#038;p=1059"},"modified":"2025-03-19T14:50:38","modified_gmt":"2025-03-19T13:50:38","slug":"calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a","status":"publish","type":"publications_science","link":"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/","title":{"rendered":"Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A"},"content":{"rendered":"<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25253771\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/25253771\/<\/a><\/p>\n<header id=\"heading\" class=\"heading\">\n<div id=\"full-view-heading\" class=\"full-view\">\n<ul id=\"full-view-identifiers\" class=\"identifiers\">\n<li><span class=\"identifier pubmed\"> <span class=\"id-label\"> PMID: <\/span> <strong class=\"current-id\" title=\"PubMed ID\">25253771<\/strong> <\/span><\/li>\n<li><span class=\"identifier doi\"> <span class=\"id-label\"> DOI: <\/span> <a class=\"id-link\" href=\"https:\/\/doi.org\/10.1182\/blood-2014-07-586347\" target=\"_blank\" rel=\"noopener\" data-ga-category=\"full_text\" data-ga-action=\"DOI\"> 10.1182\/blood-2014-07-586347 <\/a> <\/span><\/li>\n<\/ul>\n<p><span class=\"free-label\">Free article<\/span><\/div>\n<\/header>\n<div id=\"abstract\" class=\"abstract\">\n<h2 class=\"title\">Abstract<\/h2>\n<div id=\"eng-abstract\" class=\"abstract-content selected\">\n<p>Six recombinant factor VIII (rFVIII) products have been marketed worldwide. In 2013, the Research of Determinants of Inhibitor Development (RODIN) study group reported an unexpectedly high risk of inhibitor development with a second-generation full-length rFVIII (Product D) in previously untreated patients (PUPs) with severe hemophilia A (HA). In 1994, French public health authorities established a prospective cohort to monitor hemophilia treatment safety. A PUP subgroup was designed to investigate inhibitor risk factors. We analyzed this subcohort in view of the RODIN findings. After excluding 50 patients who participated in the RODIN study, the primary analysis focused on 303 boys with severe HA first treated with a rFVIII product. A clinically significant inhibitor was detected in 114 boys (37.6%). The inhibitor incidence was higher with Product D vs the most widely used rFVIII product (adjusted hazard ratio [aHR], 1.55; 95% confidence interval [CI], 0.97-2.49). Similar results were found for high-titer inhibitors and in 10 sensitivity analyses. No heterogeneity was observed between RODIN and our results. Combined aHRs were 1.58 (95% CI, 1.17-2.14) for all inhibitors and 1.70 (95% CI, 1.15-2.52) for high-titer inhibitors. Our results confirm the higher immunogenicity of Product D vs other rFVIII products in PUPs with severe HA.<\/p>\n<\/div>\n<\/div>\n<p id=\"copyright\" class=\"copyright\">\u00a9 2014 by The American Society of Hematology.<\/p>\n","protected":false},"parent":0,"template":"","keyword":[],"class_list":["post-1059","publications_science","type-publications_science","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A - FranceCoag<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A - FranceCoag\" \/>\n<meta property=\"og:description\" content=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25253771\/ PMID: 25253771 DOI: 10.1182\/blood-2014-07-586347 Free article Abstract Six recombinant factor VIII (rFVIII) products have been marketed worldwide. In 2013, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/\" \/>\n<meta property=\"og:site_name\" content=\"FranceCoag\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-19T13:50:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\\\/\",\"url\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\\\/\",\"name\":\"Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A - FranceCoag\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#website\"},\"datePublished\":\"2019-03-19T13:43:39+00:00\",\"dateModified\":\"2025-03-19T13:50:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications scientifiques\",\"item\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/\",\"name\":\"FranceCoag\",\"description\":\"La cohorte FranceCoag accompagne plus de 10.000 patients atteints d\u2019une maladie h\u00e9morragique\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#organization\",\"name\":\"FranceCoag\",\"url\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.francecoag.org\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/logo-france-COAG-1.png\",\"contentUrl\":\"https:\\\/\\\/www.francecoag.org\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/logo-france-COAG-1.png\",\"width\":600,\"height\":260,\"caption\":\"FranceCoag\"},\"image\":{\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A - FranceCoag","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/","og_locale":"en_US","og_type":"article","og_title":"Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A - FranceCoag","og_description":"https:\/\/pubmed.ncbi.nlm.nih.gov\/25253771\/ PMID: 25253771 DOI: 10.1182\/blood-2014-07-586347 Free article Abstract Six recombinant factor VIII (rFVIII) products have been marketed worldwide. In 2013, [&hellip;]","og_url":"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/","og_site_name":"FranceCoag","article_modified_time":"2025-03-19T13:50:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/","url":"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/","name":"Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A - FranceCoag","isPartOf":{"@id":"https:\/\/www.francecoag.org\/en\/#website"},"datePublished":"2019-03-19T13:43:39+00:00","dateModified":"2025-03-19T13:50:38+00:00","breadcrumb":{"@id":"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.francecoag.org\/en\/publications_science\/calvez-t-et-al-recombinant-factor-viii-products-and-inhibitor-development-in-previously-untreated-boys-with-severe-hemophilia-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.francecoag.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications scientifiques","item":"https:\/\/www.francecoag.org\/en\/publications_science\/"},{"@type":"ListItem","position":3,"name":"Calvez T et al\u00a0: Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A"}]},{"@type":"WebSite","@id":"https:\/\/www.francecoag.org\/en\/#website","url":"https:\/\/www.francecoag.org\/en\/","name":"FranceCoag","description":"La cohorte FranceCoag accompagne plus de 10.000 patients atteints d\u2019une maladie h\u00e9morragique","publisher":{"@id":"https:\/\/www.francecoag.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.francecoag.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.francecoag.org\/en\/#organization","name":"FranceCoag","url":"https:\/\/www.francecoag.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.francecoag.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.francecoag.org\/wp-content\/uploads\/2023\/12\/logo-france-COAG-1.png","contentUrl":"https:\/\/www.francecoag.org\/wp-content\/uploads\/2023\/12\/logo-france-COAG-1.png","width":600,"height":260,"caption":"FranceCoag"},"image":{"@id":"https:\/\/www.francecoag.org\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/publications_science\/1059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/publications_science"}],"about":[{"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/types\/publications_science"}],"version-history":[{"count":1,"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/publications_science\/1059\/revisions"}],"predecessor-version":[{"id":1060,"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/publications_science\/1059\/revisions\/1060"}],"wp:attachment":[{"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/media?parent=1059"}],"wp:term":[{"taxonomy":"keyword","embeddable":true,"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/keyword?post=1059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}